4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.60
+0.12 (1.42%)
Mar 9, 2026, 2:22 PM EDT - Market open
4D Molecular Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Market Capitalization | 439 | 257 | 866 | 719 | 705 | 1,098 | |
| Market Cap Growth | 103.20% | -70.27% | 20.40% | 2.03% | -35.79% | - | |
| Enterprise Value | 87 | -268 | 562 | 497 | 478 | 1,185 | |
| Last Close Price | 8.48 | 5.57 | 20.26 | 22.21 | 21.94 | 41.45 | |
| PS Ratio | 3639.62 | 6959.14 | 41.80 | 229.93 | 39.09 | 80.68 | |
| PB Ratio | 1.07 | 0.50 | 2.81 | 3.11 | 2.21 | 4.28 | |
| P/TBV Ratio | 1.18 | 0.50 | 2.81 | 3.11 | 2.21 | 4.28 | |
| EV/Sales Ratio | 723.25 | - | 27.10 | 158.89 | 26.50 | 87.05 | |
| Debt / Equity Ratio | 0.06 | 0.05 | 0.05 | 0.07 | 0.05 | - | |
| Net Debt / Equity Ratio | -0.95 | -0.94 | -0.92 | -0.87 | -0.94 | -1.08 | |
| Net Debt / EBITDA Ratio | 1.57 | 2.63 | 2.62 | 1.88 | 4.28 | 5.01 | |
| Net Debt / FCF Ratio | 1.89 | 3.48 | 3.62 | 2.06 | 3.82 | 5.33 | |
| Asset Turnover | 0 | 0 | 0.07 | 0.01 | 0.06 | 0.08 | |
| Quick Ratio | 8.22 | 14.58 | 15.21 | 13.58 | 15.21 | 16.62 | |
| Current Ratio | 8.42 | 14.92 | 15.65 | 14.02 | 15.69 | 16.88 | |
| Return on Equity (ROE) | -45.38% | -39.31% | -37.41% | -39.06% | -24.79% | -39.59% | |
| Return on Assets (ROA) | -27.64% | -26.08% | -23.45% | -22.35% | -13.89% | -20.44% | |
| Return on Capital Employed (ROCE) | -58.70% | -35.40% | -35.20% | -44.70% | -21.20% | -20.90% | |
| Earnings Yield | -47.89% | -62.48% | -11.64% | -14.94% | -10.11% | -5.16% | |
| FCF Yield | -42.37% | -53.74% | -9.07% | -13.65% | -11.10% | -4.73% | |
| Buyback Yield / Dilution | -10.07% | -37.86% | -20.95% | -16.66% | -331.23% | -25.05% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.